CA-GUPSHUP
20.12.2021 12:02:34 CET | Business Wire | Press release
Gupshup, the leader in conversational messaging, today announced the launch of a WhatsApp-based commerce solution that can enable any business to create a digital “storefront” on WhatsApp. Businesses can enable conversational journeys across every stage of the buying process: pre-purchase, purchase, and post-purchase. Based on WhatsApp’s recently launched commerce capability, Gupshup can help a business manage the complete buying experience on WhatsApp. With more than two billion active monthly users in 180 countries using WhatsApp, it is the ideal conversational commerce platform for businesses. This full-featured commerce solution also leverages Gupshup's recently launched 1-Click Bill Pay feature, which enables businesses to collect payments via WhatsApp and other messaging apps.
With Gupshup’s WhatsApp-based commerce solution, a business can create a product catalog on WhatsApp, converse with customers via AI-powered chatbots for product discovery, guide them through checkout and payment, and support them 24/7 with chatbots and live agents. New interactive elements such as multi-product messages make it simpler for businesses to showcase their offerings through the store’s catalog.
This enables businesses to present their offerings through structured experience with images and organized product details. Customers can also add preferred items to their carts on WhatsApp, interact with the businesses in real time, and make payment through Gupshup’s recently launched 1-Click Bill Pay link, all without leaving the chat window. Many businesses already leverage WhatsApp for pre-purchase and post-purchase journeys, and with the newly available Commerce features, they can now manage the entire buying journey for customers on the world’s most popular messaging app.
A few interesting facts about WhatsApp for Business1 :
- Over 175 million people message a business account on WhatsApp every day2
- 68 percent of users say WhatsApp is the easiest way of contacting a business3
- 71 percent feel more confident about a business after messaging on WhatsApp3
“Gupshup offers the most advanced, comprehensive, and easy-to-use conversational commerce platform,” said Gaurav Kachhawa, Chief Product Officer, Gupshup. “Our goal is to enable every business, large and small, to get started with commerce through WhatsApp quickly and easily as well as realize the full potential of this capability to transform their business.”
“As one of the earliest Solution Provider partners of WhatsApp, we have already helped thousands of businesses across the world go live on WhatsApp Business. Our knowledgeable sales and solutions teams, along with a network of global partners, help businesses accelerate their digital transformation,” explained Ravi Sundararajan, COO, Gupshup. “We are seeing strong demand for the new Commerce features, and the early results for businesses are promising. This is certainly going to revolutionize the way businesses conduct e-commerce.”
Explore Gupshup’s WhatsApp-based Commerce Solution
About Gupshup
Gupshup enables better customer engagement through conversational messaging. Gupshup is the leading conversational messaging platform, powering over 6 billion messages per month. Across verticals, thousands of large and small businesses in emerging markets use Gupshup to build conversational experiences across marketing, sales and support. Gupshup's carrier-grade platform provides a single messaging API for 30+ channels, a rich conversational experience-building tool kit for any use case and a network of emerging market partnerships across messaging channels, device manufacturers, ISVs and operators. With Gupshup, businesses have made conversations an integral part of their customer engagement success. Gupshup is present in India, LATAM, South East Asia, Middle East, Eastern Europe, Africa and the United States. Visit www.gupshup.io . Converse with the Gupshup bot.
- https://blog.whatsapp.com/two-billion-users-connecting-the-world-privately/?lang=en
- https://blog.whatsapp.com/shopping-payments-and-customer-service-on-whatsapp
- “Motivations and Mindsets in Messaging” by Sentient Decision Science (Facebook-commissioned study of 8,157 people who use Messenger, WhatsApp and/or Instagram Direct on a daily basis), ages 18+ in the US, UK, BR and IN, June 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom